This page is updated frequently with new Peptide-related patent applications.
|| List of recent Peptide-related patents
|Biomarkers for seizures|
The application relates to markers for seizures and epilepsy. Polypeptide expression panels or arrays are provided, comprising one or more probes capable of binding specific polypeptides in blood plasma or blood serum of a mammalian subject.
The Trustees Of The University Of Pennsylvania
|Ratiometric assay for hydrolytic enzyme quantification|
The invention refers to a nanoparticle comprising (i) a core comprising a first population of quantum dots (qds) embedded in silica, (ii) a shell comprising a second population of qds embedded in silica, (iii) at least one biomolecule selected from a peptide, a nucleic acid, a carbohydrate or a lipid which comprises a cleavage site that is susceptible of being cleaved by a hydrolytic enzyme, said biomolecule being bound to the surface of the shell through a moiety, and (iv) a photoluminescent label for each biomolecule, wherein the label is bound to the part of the biomolecule which detaches from the nanoparticle after cleavage of said biomolecule by a hydrolytic enzyme, wherein the first and second qd populations have different maximum photoluminescence emission wavelengths, and only the second qd population is susceptible of producing forster resonance energy transfer (fret) with the photoluminescent label.. .
InstituciÓ Catalana De Recerca I Estudis AvanÇats
|Method for analysis of compounds with amino group and analytical reagent therefor|
The present invention provides a method for the analysis of a compound with amino group (e.g., an amino acid or peptide) contained in a sample and convenient manner with a high sensitivity. The compound with amino group in a sample containing the compound with amino group is labeled with a specific carbamate compound such as p-trimethylammonium anilyl-n-hydroxysuccinimidyl carbamate iodide to enhance the selectivity and sensitivity.
Ajinomoto Co., Inc.
|Methods and characteristics for the diagnosis of acute lymphoblastic leukemia|
Methods for identification of leukemia or a genetic predisposition to leukemia are provided that are particularly applicable to acute lymphoblastic leukemia (all). A novel heterozygous germline variant, c.547g>a (p.gly183ser) in the octapeptide domain of pax5, is used to identify those individuals with an enhanced risk or predisposition to all..
Memorial Sloan-kettering Cancer Center
|Methods and kits for labeling cellular molecules|
Methods of uniquely labeling or barcoding molecules within a cell, a plurality of cells, and/or a tissue are provided. Kits for uniquely labeling or barcoding molecules within a cell, a plurality of cells, and/or a tissue are also provided.
University Of Washington
|Glycated hexapeptide oxidase and use thereof|
The present invention provides a protein comprising an amino acid sequence in which arginine at position 61 of a protein comprising the amino acid sequence represented by seq id no: 1 is substituted to an amino acid selected from the group consisting of glycine, alanine, valine, leucine, serine, threonine, proline, cysteine, methionine, asparagine, glutamine, and aspartic acid; and a method for measuring a glycated hemoglobin in a sample, wherein the method comprises reacting a glycated hemoglobin in a sample with a protease to produce a glycated hexapeptide, then reacting the produced glycated hexapeptide with the aforementioned protein, and measuring a substance produced or consumed by the reaction.. .
|Methods for the expression of peptides and proteins|
The present invention lies in the field of molecular biology, recombinant peptide and protein expression and relates to methods comprising nucleic acid sequences comprising allocrites of t1sss or fragments thereof for the efficient production of recombinant pe ois and pr oi. The allocrites or fragments thereof improve the expression of peoi and pr oi as ib and function as ib-tags..
|Methods and compositions for target dna modification|
The disclosure provides compositions and methods for increasing efficiency of cas9-mediated target dna modification. Specifically, the disclosure provides compositions and methods for carrying out site-directed modification of a target dna, the methods comprising contacting the target dna with: a) a complex comprising a cas9 polypeptide and a guide rna, and b) a rad51 polypeptide.
The Regents Of The University Of California
|Wheat stem rust resistance gene|
The present invention relates to a transgenic plant which has integrated into its genome an exogenous polynucleotide encoding a polypeptide which confers resistance to puccinia graminis f sp. Tritici, such as the ug99 group of races puccinia graminis f.
Commonwealth Scientific And Industrial Research Organisation
|Methods of increasing abiotic stress tolerance and/or biomass in plants|
Provided are methods of increasing the tolerance of a plant to abiotic stresses and/or increasing the biomass and/or increasing the yield of a plant by expressing within the plant an exogenous polynucleotide encoding a polypeptide homologous to seq id no:240, such as the polynucleotide set forth by seq id no:14.. .
Plants having one or more enhanced yield-related traits and a making the same
A method for enhancing one or more yield-related traits in plants relative to control plants comprises modulating expression in a plant of a nucleic acid encoding a pae1 (pectin acetylesterase) polypeptide. Pae1-encoding nucleic acids, and constructs comprising the same, are used in performing the method, and plants having one or more enhanced yield-related traits are obtained..
Basf Plant Science Compnay Gmbh
Method for inactivating target transcription factor using artificial small interfering peptide and use thereof
The present invention relates to a method for targeted inactivation of transcription factor using an artificial small interfering peptide and a use thereof. According to the present invention, an artificial small interfering peptide (a-sipep) as a truncated from of the transcription factor for regulating transcription by dimerization was produced.
Snu R&db Foundation
Novel genes involved in biosynthesis
The invention provides a novel myb class transcription factor gene (nucleic acid sequences, protein sequences, and variants and fragments thereof) designated myb14 by the applicants, that is useful for manipulating the production of flavonoids, specifically condensed tannins, in plants. The invention provides the isolated nucleic acid molecules encoding proteins with at least 70% identity to any one of myb14 polypeptide sequences of seq id no: 14 and 46 to 54.
Grasslanz Technology Limited
Protein production in plants
The present disclosure relates to methods and constructs for producing heterologous peptides and proteins in plants in a safe and controlled manner. One aspect of the present invention provides a method of producing heterologous protein in a transformed potato plant using an expression cassette comprising a gene coding for a protein or peptide of interest and a marker gene, a nucleotide sequence capable of suppressing patatin expression, along with a nucleotide sequence capable of suppressing cd4b expression, and/or a nucleotide sequence capable of overexpressing p19.
J.r. Simplot Company
Methods and compositions for rna-directed target dna modification and for rna-directed modulation of transcription
The present disclosure provides a dna-targeting rna that comprises a targeting sequence and, together with a modifying polypeptide, provides for site-specific modification of a target dna and/or a polypeptide associated with the target dna. The present disclosure further provides site-specific modifying polypeptides.
University Of Vienna
Amino acid sequence presenting fusion polypeptide and its use
Wherein the second polypeptide is a polypeptide with peptidyl-prolyl cis/trans-isomerase activity (ppiase activity) or is derived from the fkbp-fold domain family, wherein x1 is inserted in place of the insert-in-flap-domain of the second polypeptide.. .
Suppression of itch
The invention provides a polypeptide, for use in suppressing or treating itch, wherein the polypeptide comprises: a non-cytotoxic protease, which protease is capable of cleaving a snare protein in an itch-specific drg neuron or a pruriceptor; a targeting moiety (tm) that is capable of binding to a binding site on the itch-specific drg neuron or a pruriceptor, which binding site is capable of undergoing endocytosis to be incorporated into an endosome within the itch-specific drg neuron or a pruriceptor, and wherein said itch-specific drg neuron or a pruriceptor expresses said snare protein; and a translocation domain that is capable of translocating the protease from within an endosome, across the endosomal membrane and into the cytosol of the itch-specific drg neuron or a pruriceptor; with the proviso that the polypeptide is not a clostridial neurotoxin (holotoxin) molecule.. .
Ipsen Bioinnovation Limited
Methods of generating and screening for lytic chimeric polypeptides
The present invention relates to novel methods of generating and screening for chimeric polypeptides, which can be used in the treatment and prophylaxis of pathogenic bacterial contamination, colonisation and infection. The novel methods are based on random recombination of protein domains, and the chimeric polypeptides obtainable by the methods according to the invention are characterized in that they comprise at least one enzymatic active domain (ead) and at least one cell binding domain (cbd).
Hyglos Invest Gmbh
Polymer suitable for use in cell culture
A process for making an oligo(alkylene glycol) functionalized co-polyisocyanopeptide, wherein the process includes the steps of: i) copolymerizing a first comonomer of an oligo(alkylene glycol) functionalized isocyanopeptide grafted with a linking group and a second comonomer of a non-grafted oligo(alkylene glycol) functionalized isocyanopeptide, wherein the molar ratio between the first comonomer and the second comonomer is 1:500 and 1:30 and ii) adding a reactant of a spacer unit and a cell adhesion factor to the copolymer obtained by step i), wherein the spacer unit is represented by general formula a-l-b, wherein the linking group and group a are chosen to react and form a first coupling and the cell adhesion factor and group b are chosen to react and form a second coupling, wherein the first coupling and the second coupling are independently selected from the group consisting of alkyne-azide coupling, dibenzocyclooctyne-azide coupling, oxanorbornmadiene-based-azide couplings, vinylsulphone-thiol coupling, maleimide-thiol coupling, methyl methacrylate-thiol coupling, ether coupling, thioether coupling, biotin-strepavidin coupling, amine-carboxylic acid resulting in amides linkages, alcohol-carboxylic acid coupling resulting in esters linkages and nhs-ester (n-hydroxysuccinimide ester)-amine coupling and wherein group l is a linear chain segment having 10-60 bonds between atoms selected from c, n, o and s in the main chain.. .
Stichting Katholieke Universiteit
Adam22 for use as a prognostic variable, and target for therapy, of a metastatic breast cancer disease
A method of diagnosing metastatic potential of a breast cancer in an individual with breast cancer is described. The method comprises a step of assaying a breast cancer tumour sample from the patient for expression of a disintegrin and metalloproteinase 22, (adam22), wherein expression of adam22 correlates with increased potential for metastasis compared with a patient who is adam22 negative.
Royal College Of Surgeons In Ireland
Anti-ctla4, anti-glut2 protein for the treatment of type 1 diabetes
The disclosure relates to a protein composed of a first polypeptide or polypeptide domain having a first specific binding activity for cytotoxic t-lymphocyte antigen 4 (ctla-4) expressed on a t-cell cell surface and a second specific binding activity for glucose transporter 2 (glut2) or an extracellular ectodomain thereof expressed on a pancreatic β-cell surface, wherein binding of the first polypeptide or polypeptide domain to ctla-4 induces a ctla-4 specific agonist response in the t-cell, and binding of the second polypeptide or polypeptide domain to glut2 or an ectodomain thereof does not inhibit glut2 glucose transporter function, wherein said agonist response in the t-cell induces a response that reduces immunoreactivity against pancreatic β-cells.. .
The Board Of Trustees Of The University Of Illinois
Fc variants with improved complement activation
The present disclosure relates to polypeptide variants having modified fc domains with improved potency and efficacy in activation of complement-dependent cytotoxicity.. .
Abb Vie Biotherapeutics Inc.
Methylation and acetylation sites
The disclosure features over 5000 methylation and acetylation sites identified in human cell line, human serum and mouse tissues, peptides (including aqua peptides) comprising a methylation or acetylation site of the disclosure, antibodies specifically bind to a methylation or acetylation site of the disclosure, and diagnostic and therapeutic uses of the above.. .
Cell Signaling Technology, Inc.
Method for refining protein including self-cutting cassette and use thereof
The present invention relates to a self-cleaving fusion protein including a target protein, a peptide consisting of amino acid sequence represented by lpxtg, a domain of sortase a having cleaving function, and a tag, which are sequentially positioned from the amino terminal; a nucleic acid encoding the same; an expression vector including the nucleic acid of the present invention; and a cell transformed with the expression vector of the present invention. In addition, the present invention relates to a method for refining a target protein including culturing, dissolving, and purifying the transformed cell, and a method for preparing a therapeutic antibody-drug conjugate by using the purifying method..
Scripps Korea Antibody Institute
Stabilized receptor polypeptides and uses thereof
The present invention provides stabilized activin iib receptor polypeptides and proteins capable of binding and inhibiting the activities of activin a, myostatin, or gdf-11. The present invention also provides polynucleotides, vectors and host cells capable of producing the stabilized polypeptides and proteins.
Therapeutic delivery vesicles
The present invention pertains to inter alia therapeutic delivery vesicles, for instance exosomes or microvesicles, comprising polypeptide constructs, methods for producing said therapeutic delivery vesicles, pharmaceutical compositions and medical uses thereof. The therapeutic polypeptide constructs comprised in the extracellular delivery vesicles enable sequestering target molecules of interest, to treat e.g.
T cell receptors
The present invention relates to t cell receptors (tcrs) which bind the hla-a2 restricted fmnkfiyei (158-166) peptide epitope derived from α fetoprotein (afp). Certain preferred tcrs of the invention demonstrate excellent binding characteristics and specificity profiles for this afp epitope.
Peptides with enhanced stability and their use in methods for treating diseases
The invention provides peptides that are useful for treating or preventing, or preventing the progression of a disorder associated with aberrant tdf polypeptide or tdfrp compound target molecule expression or activity, for example a kidney disease or disorder, in a subject. The invention also provides methods of treating a subject having a disorder associated with aberrant tdf polypeptide or tdfrp compound target molecule expression or activity, such as a kidney disease or disorder, comprising administering to the subject an effective amount of the peptides of the invention..
Thrasos Innovation, Inc.
Fusion proteins with dual receptor agonist activities
The present disclosure relates to heterodimeric fusion proteins comprising two polypeptides, the first polypeptide comprising a first peptide (p1), a linker (l1), and a fc region (f1), the second polypeptide comprising a second peptide (p2), a linker (l2), and an fc region (f2), wherein p1 and p2 are each independently selected from glp-1, glp-1 analogues, glucagon, glucacon analogues, gip, gip analogues, oxyntomodulin, oxyntomodulin analogues, exendin and exendin analogues; wherein f is selected from an igg fc, an iga fc, an ige fc, an iggm fc, and their analogues; wherein the c-terminals of the peptides are linked, though the linker l, to the n-terminals of the fc region f. In one embodiment, the fusion proteins disclosed herein have agonist activity against at least two of the glp-1 receptor, the gip receptor, and the glucagon receptor..
Askgene Pharma, Inc.
Glucagon-like peptide-2 compositions and methods of making and using same
The present invention relates to compositions comprising glp-2 protein or variants thereof linked to extended recombinant polypeptide (xten), isolated nucleic acids encoding the compositions and vectors and host cells containing the same, and methods of making and using such compositions in the treatment of glp-2-related conditions.. .
Amunix Operating Inc.
Engineered polypeptides having enhanced duration of action
Compounds are provided having inter alia good duration of action, high potency and/or convenient dosing regimens including once weekly administration. The compounds are engineered polypeptides which incorporate an albumin binding domain in combination with one or more biologically active polypeptides.
Aegerion Pharmaceuticals, Inc.
Synaptogenic protein tagged with biotin and reconstitution of artificial synapse by using same
Disclosed is a polypeptide containing an extracellular domain of a synaptogenic protein, and a method for manufacturing a nerve cell, a complex containing a biotin tagged at the c-terminus of the polypeptide, an artificial synapse inducer for coupling the composite to a streptavidin (sav)-coated substrate and a nerve cell. The complex tagged with a biotin at the c-terminus of the polypeptide containing the extracellular domain of the synaptogenic protein, such as neuroligin-1, can display activity by being attached to the sav-coated substrate to adjust the orientation thereof without help of a supported lipid bilayer.
Seoul National University R&db Foundation
Oxidized a beta peptide
The invention provides an aβ peptide aggregation inhibitor, an aβ peptide toxicity reducing agent, and a preventive and/or therapeutic agent for alzheimer's disease. The oxidized aβ peptide in which one or more amino acid residues of aβ peptide have been oxidized (excluding an oxidized aβ peptide in which only met has been oxidized)..
Japan Science And Technology Agency
Colon disease targets and uses thereof
The present invention provides a method for diagnosing and detecting diseases associated with colon. The present invention provides one or more proteins or fragments thereof, peptides or nucleic acid molecules differentially expressed in colon diseases (ccat) and antibodies binds to ccat.
Porcine pseudorabies virus, vaccine composition and preparation method and use thereof
Provided in embodiments of the present invention is a vaccine composition including an immune amount of attenuated live vaccine, inactivated vaccine, subunit vaccine, synthetic peptide vaccine, or genetically engineered vaccine of the porcine pseudorabies virus strain. The vaccine composition can effectively induce antibody generation, and prevent infections of virulent strains of the porcine pseudorabies virus, and provides effective protection for pigs..
Pulike Biological Engineering, Inc.
Biosynthetic proline/alanine random coil polypeptides and their uses
The present invention relates to a biosynthetic random coil polypeptide or a biosynthetic random coil polypeptide segment or biosynthetic conjugate, wherein said biosynthetic random coil polypeptide, said biosynthetic random coil polypeptide segment or said biosynthetic conjugate comprises an amino acid sequence consisting solely of proline and alanine amino acid residues, wherein said amino acid sequence consists of at least about 50 proline (pro) and alanine (ala) amino acid residues. Said at least about 50 proline (pro) and alanine (ala) amino acid residues may be (a) constituents) of a heterologous polypeptide or an heterologous polypeptide construct.
Cosmetic composition for improving skin conditions comprising fusion protein
The present invention relates to a fusion protein comprising a skin-penetrating peptide, a polynucleotide encoding the fusion protein, an expression vector comprising the polynucleotide, a transformant comprising the expression vector, a method for preparing the fusion protein, a cosmetic composition for improving skin conditions, which comprises the fusion protein, and a pharmaceutical composition for external skin use, which comprises the fusion protein. The fusion protein of the invention comprises a skin-penetrating peptide bound to a physiologically active protein.
Lg Household & Health Care Ltd.
Hormone secretion regulator, composition containing same, and controlling hormone secretion using same
Provided are a hormone secretion modulator including a peptide derived from telomerase, more particularly, a peptide including an amino acid sequence of seq id no: 1, an amino acid sequence having a sequence identity of at least 80% with seq id no: 1, or a fragment thereof, a pharmaceutical composition including the hormone secretion modulator, and a use of the pharmaceutical composition for treatment, alleviation, or prevention of diseases caused by excessive or deficient levels hormones.. .
Gemvax & Kael Co., Ltd.
Peptide and complex of same, scaffold for tissue repair and surface treatment same, and surface treatment solution or set of treatment solutions
Provided are a peptide that enables surface treatment of a scaffold for tissue repair that makes it possible to accelerate the repair of living tissue without using a material that negatively affects the repair of living tissue, a complex containing this peptide, a scaffold for tissue repair surface treated using this peptide or this complex, a surface treatment method for a scaffold for tissue repair using this peptide or this complex, and a treatment solution or set of treatment solutions to be used in this surface treatment method. Surface treatment of a scaffold for tissue repair is conducted by combining glycosaminoglycan and a peptide containing adhesive sites and basic sites each comprising predetermined amino acid residues..
Jms Co., Ltd.
Peptide nucleic acid probe (pna), kit and detection of aspergillus fumigatus and applications thereof
The present invention also includes the development of the kit of detection and respective procedure for the aspergillus fumigatus identification in clinical samples.. .
Peptide-resin conjugate and use thereof
The present invention relates to a peptide-resin conjugate of formula (2), wherein: pr1 is selected from h, alkyl, aryl, aralkyl, acyl, aroyl and a protecting group; y is a direct bond; or an optionally protected natural or unnatural amino acid residue; or a peptide comprising 2 to 200 natural or unnatural amino acid residues, each of which is optionally protected; dia is a natural or unnatural diamino acid; a is a polymer resin conjugated to the side chain amino function of the diamino acid; x is an optionally protected natural or unnatural amino acid residue; or a peptide comprising 2 to 15 natural or unnatural amino acid residues, each of which is optionally protected; r1, and r2 are each independently selected from h, alkyl, aryl, aralkyl, nh2, nh—co—nh2. Further aspects of the invention relate to a process of preparing peptide-resin conjugates of formula (2), and their use in the preparation of peptides..
Chemical & Biopharmaceutical Laboratories Of Patras S.a.
Compounds for binding to the platelet specific glycoprotein iib/iiia and their use for imaging of thrombi
The present invention relates to novel fluorine containing compounds, methods for their preparation, the intermediates of the synthesis, their use as diagnostic agents, especially for imaging of thrombi. The invention relates to positron emission tomography (pet) agents and associated precursor reagents, and methods for producing such radiolaveled agents for imaging of thrombi in a mammalian body.
Piramal Imaging Sa
Progenitor endothelial cell capturing with a drug eluting implantable medical device
A medical device for implantation into vessels or luminal structures within the body is provided, which stimulates positive blood vessel remodeling. The medical device, such as a stent and a synthetic graft, is coated with a pharmaceutical composition consisting of a controlled-release matrix and one or more pharmaceutical substances for direct delivery of drugs to surrounding tissues.
Orbusneich Medical, Inc.
Gelatin sponge comprising an active ingredient, its preparation and use
The present invention is directed to a method for manufacturing a cross-linked gelatin sponge having a surface by providing a cross-linked gelatin sponge, wetting the surface of the sponge by applying a sufficient amount of liquid comprising a protein or peptide active ingredient, wherein a sufficient amount of liquid is one that retains the flexibility of the sponge even after drying. The sponge is then dried the sponge to obtain a flexible, dry and ready to use cross linked gelatin sponge having a layer of protein or peptide active ingredient on the surface thereof..
Omrix Biopharmaceuticals Ltd.
Glycoengineered antibody drug conjugates
The current disclosure provides binding polypeptides (e.g., antibodies), and targeting moiety conjugates thereof, comprising a site-specifically engineered glycan linkage within native or engineered glycans of the binding polypeptide. The current disclosure also provides nucleic acids encoding the antigen-binding polypeptides, recombinant expression vectors and host cells for making such antigen-binding polypeptides.
Bifunctional protein anchors
The disclosure relates to the areas of immunology and vaccine delivery. More specifically, it relates to a bacterial vaccine delivery technology with built-in immunostimulatory properties which allow the immobilization of any antigen of interest, without prior antigen modification.
Applied Nanosystems B.v.
Structure, manufacturing and uses of human-derived cell-permeable peptides conjugated with specific biologically active cargo peptides
Embodiments disclosed herein provide compositions for conjugates, including fusion proteins, and methods of using them to treat a variety of conditions. In some embodiments, the conjugates and/or fusion proteins incorporate a 60-amino acid human homeodomain (e.g., peptides derived from human hox genes), to translocate functional and regulatory peptides and proteins or other biologically active molecules such as nucleic acids, which are not naturally associated with the human homeodomain, across cell and nuclear membranes to intended sites of action without provoking an unwanted immune response that may reduce exposure to the conjugate and/or result in a clinical adverse event.
Portage Pharmaceuticals Ltd.
The present invention provides a composition for provoking an immune response in a patient to an autoantigen target, the composition comprising the target conjugated a carrier polypeptide.. .
The University Of Birmingham
Mammalian milk osteopontin for enhancing immune responsiveness
The disclosed invention provides mammalian milk osteopontin and/or an active truncation or active peptide thereof for improving immune responsiveness to an infectious disease in a mammal, for example a human subject, as well as enhancing the efficacy of vaccination for the prophylactic or therapeutic treatment of an infectious disease in mammals, such as humans. The invention further provides a vaccine system, for use in the prophylactic or therapeutic treatment of an infectious disease in a mammal, comprising a vaccine and a mammalian milk osteopontin and/or an active truncation or active peptide thereof for oral administration to a mammal, as well as methods of enhancing immune resistance to an infectious disease in a mammal by administration of a vaccine and a mammalian milk osteopontin and/or an active truncation thereof..
Arla Foods Amba
Influenza virus vaccines and uses thereof
Provided are influenza hemagglutinin stem domain polypeptides comprising (a) an influenza hemagglutinin ha1 domain that comprises an ha1 n-terminal stem segment comprising the amino acids from position 1 to position x, preferably from position p to position x, of the ha1 domain, covalently linked by a linking sequence of 0-50 amino acid residues to an ha1 c-terminal stem segment, comprising the amino acids from position y to and including the c-terminal amino acid of the ha1 domain; and (b) an influenza hemagglutinin ha2 domain, wherein the hemagglutinin stem domain polypeptide is resistant to protease cleavage at the junction between ha1 and ha2, and wherein one or more amino acid of the amino acids at positions 337, 340, 352, 353, 402, 406, 409, 413 and/or 416 have been mutated, as compared to the corresponding positions in wild-type influenza ha.. .
Crucell Holland B.v.
Vaccination with recombinant mycobacterium tuberculosis pknd attenuates bacterial dissemination to the brain
Vaccines comprising mycobacterium tuberculosis (m. Tuberculosis) pknd sensor polypeptides, compositions, kits, and methods of use for treating central nervous system tuberculosis are disclosed.
The Johns Hopkins University
Vaccines against pregnancy-associated malaria
The present invention relates to combinations of polypeptides or of polynucleotides corresponding to a specific region of the n-terminal portion of the var2csa protein of different parasitic families or lines of plasmodium falciparum, and to their use in the prevention of pregnancy-associated malaria. The invention also relates to immunogenic compositions and to vaccines useful for preventing malaria in pregnant women..
Institut De Recherche Pour Le DÉvelopment (ird)
An immunity-inducing agent comprising as an effective ingredient(s) a polypeptide(s) selected from the polypeptides: (a) a polypeptide consisting essentially of not less than 7 consecutive amino acids in any one of the amino acid sequences shown in seq id nos:2, 4, 6, 8, 10, 12 and 44 in sequence listing; (b) a polypeptide having a sequence identity of not less than 90% with the polypeptide (a) and consisting essentially of not less than 7 amino acids; and (c) a polypeptide comprising the polypeptide (a) or (b) as a partial sequence thereof; which polypeptide(s) has/have an immunity-inducing activity/activities, or as an effective ingredient(s) a recombinant vector(s) which comprise(s) a polynucleotide(s) encoding the polypeptide(s) and is/are capable of expressing the polypeptide(s) in vivo, is useful as a therapeutic and/or prophylactic agent for cancer, and/or the like.. .
Toray Industries, Inc.
Methods and materials for modulating deubiquitinases and ubiquitinated polypeptides
This document relates to methods and materials involved in modulating deubiquitinases (e.g., usp10 polypeptides) and/or ubiquitinated polypeptides (e.g., tumor suppressor polypeptides or mutant versions of tumor suppressor polypeptides). For example, methods and materials for increasing deubiquitinase (e.g., a usp10 polypeptide) expression or activity, methods and materials for decreasing deubiquitinase (e.g., a usp10 polypeptide) expression or activity, methods and materials for stabilizing tumor suppressor polypeptides (e.g., wild-type p53 polypeptides), methods and materials for de-stabilizing mutant versions of tumor suppressor polypeptides (e.g., mutant p53 polypeptides), and methods and materials for reducing cancer cell proliferation, increasing cancer cell apoptosis, and/or treating cancer (e.g., cancers having reduced levels of wild-type p53 polypeptides or cancers having increased levels of mutant p53 polypeptides) are provided.
Mayo Foundation For Medical Education And Research
Compositions and methods relating to myomaker-induced muscle cell fusion
The present disclosure describes the fusogenic activity of the myomaker protein. This polypeptide, when expressed in non-muscle cells, is able to drive fusion of the cell with a muscle cell, but not with other non-muscle cells.
The Board Of Regents Of The University Of Texas Sy Stem
Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition
The described invention provides compositions and methods for reducing progression of a fibrosis in a tissue of a subject selected from liver, kidney or vascular fibrosis, the progression of the fibrosis being characterized by aberrant fibroblast proliferation and extracellular matrix deposition in the tissue. The method includes administering a therapeutic amount of a pharmaceutical composition containing a polypeptide having the amino acid sequence yaraaarqarakalarqlgvaa (seq id no: 1) or functional equivalent thereof, and a pharmaceutically acceptable carrier, wherein the therapeutic amount of the polypeptide is effective to reduce progression of the fibrosis, to treat remodeling of the tissue, or a combination thereof..
Moerae Matrix, Inc.
Topical formulations of chemerin c15 peptides for the treatment of dermatological conditions
Described herein, are topical formulations for treating a dermatological disease, disorder, or condition. Topical formulations disclosed herein include a therapeutically-effective amount of a human chemerin c15 peptide formulated for dermal administration..
Rogne Bioscience, Inc.
Polypeptide having the ability to form connections of glucosyl units in alpha-1,3 on an acceptor
An isolated polypeptide having the ability to specifically form connections of glucosyl units in alpha 1,3 on an acceptor including at least one hydroxyl moiety. The polypeptide includes i) the pattern i of sequence seq id no: 1, ii) the pattern ii of sequence seq id no: 2, iii) the pattern ii of sequence seq id no: 3, iv) the pattern iv of sequence seq id no: 4 or derivates from one or several of said patterns.
Centre National De La Recherche Scientifique (cnrs)
Compositions and methods for affecting mood states
The present invention generally relates to compositions and methods for topical or transdermal delivery, e.g., for affecting mood states. In some cases, the composition may include nitric oxide and/or peptides.
Transdermal Biotechnology, Inc.
Design and construction of diverse synthetic peptide and polypeptide libraries
The present invention concerns the design and construction of diverse peptide and polypeptide libraries. In particular, the invention concerns methods of analytical database design for creating datasets using multiple relevant parameters as filters, and methods for generating sequence diversity by directed multisyntheses oligonucleotide synthesis.
Sea Lane Biotechnologies, Inc.
Bioinformatic processes for determination of peptide binding
This invention relates to the identification of peptide binding to ligands, and in particular to identification of epitopes expressed by microorganisms and by mammalian cells. The present invention provides polypeptides comprising the epitopes, and vaccines, antibodies and diagnostic products that utilize or are developed using the epitopes..
Follow us on Twitter
This listing is a sample listing of patent applications related to Peptide for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Peptide with additional patents listed. Browse our RSS directory or Search for other possible listings.